Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 3/17/20 (What's New)

Summary

  • Results from the EASIER-ANRS 138 study[De Castro 2009] and other single-arm studies[Talbot 2009; Towner 2009] suggest that when substituting one antiretroviral agent with a low genetic barrier to resistance, such as enfuvirtide, for another, such as raltegravir, in virologically suppressed patients, the background regimen will most likely be potent enough to maintain virologic suppression

Action required

Keywords: Switch Strategies

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.